dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Ramaswami, Uma |
dc.contributor.author | Beck, Michael |
dc.contributor.author | Hughes, Derralynn |
dc.contributor.author | Kampmann, Christoph |
dc.contributor.author | Botha, Jaco |
dc.contributor.author | Pintos Morell, Guillem |
dc.date.accessioned | 2021-04-16T14:31:11Z |
dc.date.available | 2021-04-16T14:31:11Z |
dc.date.issued | 2019-10-25 |
dc.identifier.citation | Ramaswami U, Beck M, Hughes D, Kampmann C, Botha J, Pintos-Morell G, et al. Cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: A 10-year fabry outcome survey (FOS) analysis. Drug Des Devel Ther. 2019;13:3705–15. |
dc.identifier.issn | 1177-8881 |
dc.identifier.uri | https://hdl.handle.net/11351/5871 |
dc.description | Agalsidasa alfa; Teràpia de reemplaçament enzimàtic; Malaltia de Fabry |
dc.description.sponsorship | The Fabry Outcome Survey is sponsored by Shire Human Genetic Therapies, Inc., a member of the Takeda group of companies. Shire International GmbH, a member of the Takeda group of companies, provided funding to Excel Medical Affairs for support in writing and editing this manuscript and participated in data collection and analysis. |
dc.language.iso | eng |
dc.publisher | Dove Medical Press |
dc.relation.ispartofseries | Drug Design, Development and Therapy;13 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Enzims - Regulació |
dc.subject | Malalties congènites |
dc.subject | Metabolisme - Trastorns |
dc.subject.mesh | Fabry Disease |
dc.subject.mesh | Enzyme Replacement Therapy |
dc.title | Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.2147/DDDT.S207856 |
dc.subject.decs | enfermedad de Fabry |
dc.subject.decs | tratamiento de sustitución enzimática |
dc.relation.publishversion | https://www.dovepress.com/cardio--renal-outcomes-with-long--term-agalsidase-alfa-enzyme-replacem-peer-reviewed-article-DDDT |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Ramaswami U, Hughes D] Royal Free London NHS Foundation Trust, Lysosomal Disorders Unit, Institute of Immunity and Transplantation, London, UK. [Beck M, Kampmann C] Centre for Paediatric and Adolescent Medicine, University Medical Centre, University of Mainz, Mainz, Germany. [Botha J] Department of Biostatistics and Programming, Takeda, Zug, Switzerland. [Pintos-Morell G] Malalties minoritàries, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Research Institute and Teaching Unit Germans Trias i Pujol. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 31749608 |
dc.identifier.wos | 000492854800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |